Article

Targeting Multiple Conserved T-Cell Epitopes for Protection against COVID-19 Moderate-Severe Disease by a Pan-Sarbecovirus Vaccine

2023-06-28

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Most of current approved vaccines, based on a Spike-only as single immunogen, fall short of producing a full-blown T-cell immunity. SARS-CoV-2 continues to evolve with ever-emergent higher-contagious mutants that may take a turn going beyond Omicron to bring about a new pandemic outbreak. New recombinant SARS-CoV-2 species could be man-made through genetic manipulation to infe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1e4543cd-96d3-5d93-913e-d0876a60f4cf
DOI: 10.1101/2023.06.28.23291948

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting Multiple Conserved T-Cell Epitopes for Protection against COVID-19 Moderate-Severe Disease by a Pan-Sarbecovirus VaccineDOI 10.1101/2023.06.28.23291948Read

UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of ConcernSemantic proximity Read

Clinical and immunological features of SARS-CoV-2 breakthrough infections in vaccinated individuals requiring hospitalizationSemantic proximity Read

A Multi-Antigen Broad-Spectrum Coronavirus Vaccine Induces Potent and Durable Cross- Protection Against Infection and Disease Caused by Multiple SARS-CoV-2 VariantsSemantic proximity Read

Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimenSemantic proximity Read

COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic StrategiesSemantic proximity Read

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-cell VaccineSemantic proximity Read

A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster ModelSemantic proximity Read

Inactivated vaccine fueled adaptive immune responses to Omicron in 2-year COVID-19 convalescentsSemantic proximity Read

Emerging SARS-CoV-2 variants of concern and potential intervention approaches.Semantic proximity Read

Expert Review of Global Real-World Vaccine Effectiveness Against SARS-CoV-2Semantic proximity Read

<strong>Efficacy of COVID-19 Vaccines Against the Omicron Variant of SARS-CoV-2</strong>Semantic proximity Read

A Beta-containing bivalent SARS-CoV-2 spike protein vaccine candidate with AS03 elicits durable and broad neutralization of variants including Omicron in macaques and confers protection in hamstersSemantic proximity Read